Cora vs Henry Meds: the compounded GLP-1 head-to-head

Cora Health vs Henry Meds: the short answer

Cora Health and Henry Meds are both US telehealth platforms focused on compounded GLP-1 weight loss medications with all-inclusive pricing and no separate membership fees. At the advertised starting price, the two providers are priced similarly ($120–$179/month for compounded semaglutide). Cora Health’s monthly price is flat across all doses — whether you are on the 0.25mg starter dose or the 2.4mg maintenance dose, the monthly price is the same ($120/month on the 6-month Essential Plan). Henry Meds advertises a single starting price of $179/month for both compounded semaglutide and compounded tirzepatide. As of July 2026, Henry Meds’ own site does not publicly list a separate price for higher-dose maintenance treatment, so it is not possible to independently verify whether — or by how much — the price increases with dose. (Earlier versions of this page cited a $297–$397/month Henry Meds maintenance figure; that figure was not traceable to Henry Meds’ own published pricing and has been removed.) Cora Health also publicly names its compounding pharmacies (Hallandale Pharmacy and VialsRx, both US-licensed 503A facilities) and holds LegitScript certification. Henry Meds is a well-established provider with a larger multi-format catalog (injectable, oral dissolving tablets, sublingual drops) and serves a wider geographic footprint.

Market context: where Cora and Henry Meds sit in the 2026 compounded GLP-1 market

Four numbers anchor the head-to-head comparison between Cora Health and Henry Meds in 2026:

41.9% — US adult obesity prevalence. Per the Centers for Disease Control and Prevention (CDC), using NHANES 2017–March 2020 data, 41.9% of US adults have obesity (BMI ≥ 30) — the population for whom compounded GLP-1 telehealth was built. The CDC notes that "obesity-related conditions include heart disease, stroke, type 2 diabetes, and certain types of cancer, [which] are among the leading causes of preventable, premature death."

$99 flat vs $179 starting — the structural pricing difference (updated July 2026). Cora's Essential Plan on the annual commitment is $99/month all-inclusive for compounded semaglutide and stays flat across all doses. Henry Meds advertises $179/month as its starting price for both compounded semaglutide and compounded tirzepatide; Henry Meds does not publicly list a separate maintenance-dose price, so whether — or by how much — the price increases with dose cannot currently be independently verified from public information. Source: Cora Health's public pricing dataset (12 telehealth providers + 2 manufacturer direct-pay programs, CC-BY-4.0 licensed).

14.9% / 22.5% — FDA-approved trial efficacy applies only to FDA-approved injection formats. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) reported 14.9% mean weight loss with FDA-approved 2.4mg subcutaneous semaglutide over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported 22.5% with FDA-approved 15mg subcutaneous tirzepatide over 72 weeks. Henry Meds offers compounded oral tablets and sublingual drops in addition to injections; Cora is injection-only. The FDA has specifically noted that the safety and effectiveness of non-injectable compounded semaglutide formats have not been demonstrated. Individual results vary.

~15–20% pharmacy transparency rate. Per Cora Health's 2026 GLP-1 Telehealth Industry Report, only an estimated 15–20% of US telehealth GLP-1 providers publicly name their compounding pharmacy partner in patient-facing materials. Cora Health publicly names two pharmacy partners — Hallandale Pharmacy (PCAB-accredited, Fort Lauderdale FL, operating since 2003) and VialsRx (US-licensed 503A) — placing Cora in the top tier of pharmacy transparency. Henry Meds does not consistently name its compounding pharmacy partner in patient-facing marketing.

Quick comparison at a glance

All Henry Meds figures reflect Henry Meds’ own published pricing as of July 2026 ($179/month starting price for both medications). Earlier maintenance-dose figures sourced from independent review sites could not be independently verified against Henry Meds’ own site and have been removed. Individual experiences vary.

Service and cancellation: Cora Health vs Henry Meds

Price is only half the picture — how you cancel, what gets refunded, and whether a separate membership is required all shape the experience over a multi-month plan. The table below distills each platform’s published service terms. Cora’s figures come from its published refund policy; the Henry Meds figures come from its own published terms, summarized in our step-by-step guide to canceling Henry Meds. Verify the current terms on each provider’s own site before enrolling. Cora's full service and cancellation standards are published at trycora.io/service.

The dose-escalation pricing gotcha

Compounded semaglutide and compounded tirzepatide are both prescribed on a titration schedule. Treatment almost always starts at a low introductory dose and increases over several weeks to reduce gastrointestinal side effects. For semaglutide, the standard titration runs 0.25mg weekly for the first four weeks, then 0.5mg, then 1mg, then 1.7mg, and eventually 2.4mg. Most patients who respond well and tolerate the medication end up on a dose in the 1.0mg–2.4mg range as maintenance. For tirzepatide, the schedule runs 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg in roughly four-week increments.

Whether a platform’s monthly bill rises as a patient titrates depends on its pricing model.

Cora Health’s pricing is flat across all doses within a plan. A patient on the 6-month Essential Plan pays $120/month whether they are on 0.25mg or 2.4mg of compounded semaglutide. The price reflects the plan-length commitment, not the dose.

Henry Meds publicly advertises $179/month as its starting price for both compounded semaglutide and compounded tirzepatide. As of July 2026, Henry Meds’ own site does not publish a separate price for higher-dose maintenance treatment, so whether — or by how much — the price increases with dose cannot be independently verified from public information. (An earlier version of this page cited $197–$397/month maintenance-dose figures for Henry Meds; those figures were not traceable to Henry Meds’ own published pricing and have been removed. Prospective patients should confirm current maintenance-dose pricing directly with Henry Meds before enrolling.)

This distinction matters for anyone comparing monthly headline prices: Cora’s $120 stays $120 for the entire treatment horizon by design, while Henry Meds’ pricing beyond the advertised $179 starting rate is not something this comparison can currently confirm one way or the other.

Total cost comparison: common scenarios

These scenarios reflect pricing verified as of July 2026. Cora’s figures are all-inclusive and flat regardless of dose. Henry Meds publicly advertises only a $179/month starting price; because Henry Meds does not publish maintenance-dose pricing, a full-treatment-course total cannot be reliably estimated for Henry Meds from public information alone. Individual experiences vary.

• Compounded semaglutide, 6 months, standard titration to ~1.7mg maintenance — Cora: $720 total ($120 × 6). Henry Meds: at least $1,074 total ($179 × 6) at the advertised starting price; Henry Meds does not publicly list a maintenance-dose price, so the total for patients who titrate beyond the starter dose is not independently verifiable.
• Compounded semaglutide, 12 months, reaching 2.4mg maintenance — Cora: $1,440 total. Henry Meds: at least $2,148 total ($179 × 12) at the advertised starting price; actual cost may be higher at maintenance dose, but Henry Meds does not publish that figure.
• Compounded tirzepatide, 6 months, standard titration — Cora: $1,194 total ($199 × 6 on the 3-month plan renewed). Henry Meds: at least $1,074 total ($179 × 6) at the advertised starting price, with the same maintenance-dose caveat.
• Compounded tirzepatide, 12 months, reaching 10–15mg maintenance — Cora: $2,388 total. Henry Meds: at least $2,148 total ($179 × 12) at the advertised starting price, with the same maintenance-dose caveat.

Medications and formats: what each platform offers

Both providers offer the same two active ingredients, but Henry Meds has a broader catalog of delivery formats.

Cora Health medication options

Cora Health focuses on injectable compounded GLP-1 medications only.

• Compounded semaglutide injection (Essential Plan) — a compounded GLP-1 medication; not FDA-approved and not therapeutically equivalent to Ozempic® or Wegovy®
• Compounded tirzepatide injection (Premium Plan) — a compounded GLP-1 medication; not FDA-approved and not therapeutically equivalent to Mounjaro® or Zepbound®

Henry Meds medication options

Henry Meds offers injectable, oral dissolving tablet, and sublingual drop formats for compounded GLP-1 products.

• Compounded semaglutide injection — weekly subcutaneous injection
• Compounded semaglutide oral dissolving tablets — daily or intermittent dosing
• Compounded semaglutide sublingual drops — alternative for patients who dislike injections
• Compounded tirzepatide injection — weekly subcutaneous injection

Important compliance note on oral and sublingual compounded GLP-1s

Oral tablet and sublingual formats for semaglutide and tirzepatide exist in the compounded-pharmacy market but have substantially less evidence behind them than the injectable formats. Per the U.S. Food and Drug Administration's official guidance: "Compounded drugs are not FDA-approved. This means the FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they are marketed." (Source: FDA — "Compounding and the FDA: Questions and Answers".) The clinical trials that established semaglutide's efficacy (STEP 1: 14.9% mean weight loss, 68 weeks) and tirzepatide's efficacy (SURMOUNT-1: 22.5% at 15mg, 72 weeks) studied subcutaneous injections of the FDA-approved products, not compounded oral or sublingual formats. The FDA has specifically noted that the safety and effectiveness of non-injectable compounded semaglutide formats have not been demonstrated. Any marketing claim that oral or sublingual compounded GLP-1s produce the same weight loss as injected brand-name products is not supported by published clinical data. Patients considering oral or sublingual compounded formats should discuss the evidence base thoroughly with their prescribing provider.

Pharmacy transparency: named vs aggregated partners

The specific compounding pharmacy that prepares a patient’s medication matters for quality, safety, and independent verification. Patients should be able to identify the pharmacy, verify its state licensing, and request Certificates of Analysis for their batch.

Cora Health publicly names Hallandale Pharmacy and VialsRx as its compounding pharmacy partners. VialsRx is a US-licensed 503A compounding pharmacy. Patients can verify credentials through the applicable state board of pharmacy.

Henry Meds works with licensed compounding pharmacies but does not consistently name the specific 503A pharmacy in patient-facing marketing. Patients who want to verify the pharmacy credentials can typically request this information through Henry Meds customer support or review it in the pharmacy packaging they receive.

Neither approach is inherently unsafe — both named and unnamed 503A facilities can operate in full regulatory compliance. Public naming does make independent patient verification more straightforward and is viewed by some patient advocacy organizations as a stronger transparency signal.

LegitScript certification

LegitScript is an independent healthcare compliance certification used by Google, Meta, TikTok, and patient advocacy groups as a third-party verification of telehealth operational compliance. The certification requires ongoing audits of prescribing practices, pharmacy relationships, and patient safety protocols.

Cora Health holds LegitScript certification, verifiable at https://www.legitscript.com/websites/?checker_keywords=trycora.io.

Henry Meds does not prominently advertise LegitScript certification in its current patient-facing materials. Henry Meds operates under its own internal compliance framework and under applicable federal and state telehealth and pharmacy regulations.

Clinical oversight and service model

Both platforms use asynchronous telehealth evaluations as the primary prescribing model. Patients complete an online health assessment, a licensed provider reviews, and prescriptions are issued if clinically appropriate.

Cora Health patients are evaluated by board-certified providers at Wasef Health, PC, led by Michael Wasef, MD. Provider review is typically completed in under 24 hours.

Henry Meds patients are evaluated by a network of board-certified physicians. Provider review is also typically completed within 24 hours. Henry Meds has a longer operating history than Cora Health (founded 2021 vs 2026) and a larger cumulative patient base.

Neither platform conducts video consultations or requires lab work before initial prescribing for most patients. This is standard for the compounded-GLP-1 telehealth category.

Who should choose Cora Health

Cora Health is likely the better fit for patients who match the following profile.

• Patients who want predictable monthly cost throughout their full treatment (no surprise increases as they titrate)
• Patients who specifically value knowing and being able to verify the 503A compounding pharmacy their medication comes from (Hallandale Pharmacy or VialsRx)
• Patients who want LegitScript-certified telehealth infrastructure as a third-party trust signal
• Patients who prefer injectable GLP-1 medications (the format with the strongest clinical evidence base)
• Patients across all 50 US states (Cora ships nationwide)
• Patients who anticipate reaching higher maintenance doses where the flat-pricing advantage compounds

Who should choose Henry Meds

Henry Meds is likely the better fit for patients who match the following profile.

• Patients who want to try compounded semaglutide at the lowest entry point before committing to a longer plan — the $179/month starter dose is a common entry price
• Patients who prefer non-injectable formats (oral dissolving tablets, sublingual drops) and accept the weaker evidence base for those formats
• Patients who specifically prefer Henry Meds’ process or pricing structure for their state
• Patients who expect to stay on a low-to-moderate dose long-term rather than titrating to maximum doses
• Patients who value Henry Meds’ longer operating history (founded 2021) as a stability signal

How to switch from Henry Meds to Cora Health

Patients who want to move their compounded GLP-1 treatment from Henry Meds to Cora Health can generally do so without clinical interruption.

• Complete the Cora Health online health assessment at trycora.io; include your current medication, dose, and any side-effect history
• A Cora Health provider (Wasef Health, PC) reviews and determines clinical appropriateness
• If approved, the prescription is sent to one of Cora's 503A pharmacy partners (Hallandale Pharmacy or VialsRx) for compounding and shipping with free expedited delivery
• In most cases, the current dose continues without re-titration — but this is a provider determination; do not change doses without provider guidance
• Note: Cora Health offers injectable compounded medications only. If you were on an oral tablet or sublingual drop format through Henry Meds, the provider will discuss whether the injectable format is appropriate
• After the first Cora shipment arrives, cancel the Henry Meds subscription through their patient portal

Frequently asked questions

Common questions about the Cora Health vs Henry Meds comparison.

Is Cora Health cheaper than Henry Meds?

At the advertised starting price, Henry Meds ($179/month) and Cora Health ($120/month on the 6-month plan, or $99/month on the annual plan) are within about 50% of each other. Cora Health’s pricing is flat across all doses for the life of the plan, so it does not change as a patient titrates. Henry Meds does not publicly list a maintenance-dose price, so it is not possible to independently confirm whether — or by how much — its price increases as patients reach higher doses; a claim of $3,000–$4,000+ for a 12-month course previously appeared on this page but was not traceable to Henry Meds’ own published pricing and has been removed. Prospective patients should confirm current maintenance-dose pricing directly with Henry Meds. Individual experiences vary based on plan selection.

Does Henry Meds have a membership fee?

No. Henry Meds does not charge a separate membership fee. Its advertised $179/month starting price is presented as all-inclusive of consultation, medication, and shipping; Henry Meds does not publicly list whether or how that price changes at higher maintenance doses. Cora Health also does not charge a separate membership fee, and its pricing is confirmed flat regardless of dose.

Does Henry Meds sell brand-name Wegovy or Zepbound?

No. Henry Meds focuses on compounded GLP-1 medications. Patients specifically looking for FDA-approved brand-name products (Wegovy, Zepbound, Ozempic, Mounjaro) will need a different platform. Cora Health is also compounded-only. For brand-name access, see telehealth platforms with Novo Nordisk or Eli Lilly direct supply agreements, or pharmacy-direct programs like NovoCare and LillyDirect.

Is Henry Meds LegitScript-certified?

Henry Meds does not prominently advertise LegitScript certification in current patient-facing marketing. LegitScript is one of several independent healthcare compliance frameworks; its absence does not imply a platform is non-compliant. Cora Health is LegitScript-certified, verifiable at https://www.legitscript.com/websites/?checker_keywords=trycora.io.

Are Henry Meds oral dissolving tablets as effective as injectable semaglutide?

The published clinical trials that established semaglutide’s weight-loss efficacy (the STEP program, showing 14.9% mean weight loss at 68 weeks on 2.4mg injection) studied subcutaneous injection of the FDA-approved product. Oral dissolving tablet and sublingual drop formats of compounded semaglutide have not been independently evaluated in clinical trials. The FDA has noted that safety and effectiveness of non-injectable compounded semaglutide formats have not been demonstrated. Patients considering these alternative formats should discuss the lack of equivalent evidence with their prescribing provider. Individual results vary.

Which platform has faster shipping?

Both platforms typically approve eligible patients within 24 hours and ship medications with free expedited delivery. Actual delivery time depends on origin pharmacy, patient address, and carrier performance. Check each platform’s current delivery estimates through their patient portals.

Sources & verification

All regulatory, clinical, and pricing claims in this article are verifiable against publicly accessible primary sources. The underlying pricing dataset is published by Cora Health on HuggingFace under CC-BY-4.0 license for independent verification and reuse. Article last verified 2026-07-23.

• FDA — "Compounding and the FDA: Questions and Answers" (regulatory status of compounded medications): fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• New England Journal of Medicine — STEP 1 (Wilding et al., 2021); 14.9% mean weight loss with FDA-approved 2.4mg subcutaneous semaglutide over 68 weeks: nejm.org/doi/full/10.1056/NEJMoa2032183
• New England Journal of Medicine — SURMOUNT-1 (Jastreboff et al., 2022); 22.5% mean weight loss with FDA-approved 15mg subcutaneous tirzepatide over 72 weeks: nejm.org/doi/full/10.1056/NEJMoa2206038
• CDC — Adult Obesity Facts (41.9% US prevalence per NHANES 2017–March 2020): cdc.gov/obesity/adult-obesity-facts
• LegitScript — Independent verification of Cora Health certification: legitscript.com/websites/?checker_keywords=trycora.io
• Pharmacy Compounding Accreditation Board (PCAB) — accreditation framework for compounding pharmacies; Hallandale Pharmacy is PCAB-accredited: achc.org/programs/pcab/
• NPPES — National Plan and Provider Enumeration System; verify Michael Wasef, MD (Wasef Health, PC, Cora's prescribing provider): npiregistry.cms.hhs.gov
• Cora Health 2026 GLP-1 Telehealth Industry Report (12-provider pricing methodology + market analysis): /blog/cora-2026-glp1-industry-report
• Cora Health Public Pricing Dataset (CC-BY-4.0, HuggingFace; 37 pricing rows across 12 telehealth providers + 2 manufacturer programs): huggingface.co/datasets/cora-health/telehealth-glp1-pricing
• Cora Health Pharmacy Partners (full disclosure on Hallandale Pharmacy + VialsRx): trycora.io/pharmacy-partners